- Conditions
- Congestive Heart Failure
- Interventions
- MCC-135, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 136
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Mental Illness, Major Depression, Schizophrenia, Bipolar Disorder
- Interventions
- My Coach Connect
- Behavioral
- Lead sponsor
- RAND
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Breast Cancer, Breast Cancer, Female, Breast Cancer, Male, Breast Neoplasms
- Interventions
- Fluoro-D-glucose-positron Emission Tomography, 2-deoxy-2-[18F]fluoro-D-glucose (FDG), Echocardiogram
- Diagnostic Test · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Breast Neoplasm Female, Arthralgia
- Interventions
- Hyaluronic Acid (HA), Placebo
- Drug · Other
- Lead sponsor
- Erin Newton
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- PI3K inhibitor BYL719, ado-trastuzumab emtansine, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Depressive Disorder, Major
- Interventions
- Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
- Drug · Behavioral
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Not listed
- Enrollment
- 144,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
- Drug
- Lead sponsor
- George W. Sledge Jr.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Primary Ciliary Dyskinesia
- Interventions
- Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
- Drug · Diagnostic Test
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 12 Years to 90 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Self-Management Group, Symptom Management Group
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • West Haven, Connecticut
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
- Interventions
- vidutolimod, cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
- Conditions
- Persistent Asthma
- Interventions
- Lung Flute
- Device
- Lead sponsor
- Medical Acoustics LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Frailty, Inflammation
- Interventions
- Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C)
- Drug · Dietary Supplement
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Habituation
- Interventions
- NO GUM, MCC (Mint Chocolate Chip gum), C (Cinnamon gum)
- Other
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Chronic Rhinosinusitis
- Interventions
- 1% Johnson's Baby Shampoo
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab emtansine [Kadcyla]
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Vinorelbine, Trastuzumab Emtansine
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Impaired Fasting Glucose
- Interventions
- psyllium, Microcrystalline Cellulose
- Dietary Supplement
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Mucociliary Clearance
- Interventions
- HFO-1234ze(E), HFA-134a
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
- Conditions
- Environmental Exposure, Ozone, Air Pollution, Genetic Susceptibility
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Primary Ciliary Dyskinesia
- Interventions
- Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC), CT of the chest, MRI of the chest
- Diagnostic Test
- Lead sponsor
- ReCode Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
- Interventions
- 225Ac-ETN029, 111In-ETN029
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
- Conditions
- Overweight, Obesity
- Interventions
- Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
- Dietary Supplement
- Lead sponsor
- Brightseed
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Addison, Illinois